| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Regeneron Pharmaceuticals (NASDAQ:REGN) through any online brokerage.
Other companies in Regeneron Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Regeneron Pharmaceuticals has a consensus price target of $809.90.
The stock price for Regeneron Pharmaceuticals (NASDAQ: REGN) is $742 last updated October 7, 2026 at 8:24 AM EDT.
There are no upcoming dividends for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
